Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions

Diabetes, Obesity and Metabolism

Volumn 3, Issue 2, 2001, Pages 73-83

  Russo, P ^a   Lozito, R ^a   Dunning, B E ^a   De Souza, Christopher J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

A 4166; Acute insulin response; Insulin secretion; Insulinotrophic agents; Sulphonylurea

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; INSULIN; NATEGLINIDE; REPAGLINIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CELL SECRETION; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPOGLYCEMIA; INDWELLING CATHETER; INSULIN RELEASE; JUGULAR VEIN; MALE; MEAL; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRITIONAL TOLERANCE; PANCREAS ISLET BETA CELL; PATHOLOGY; POSTPRANDIAL STATE; RAT; RAT STRAIN; TIME;

EID: 0034872966     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2001.00114.x     Document Type: Article

References (28)

1. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM
2. Insulin secretion in diabetes mellitus
3. Loss of early phase insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose
4. Insulin resistance and beta cell function in the development of non-insulin-dependent diabetes mellitus: Prospective studies of Pima Indians
5. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance
6. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes
7. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys (B28, Pro (B29) ] in IDDM
8. [Lys (B28, Pro (B29)]-human insulin: A rapidly absorbed analogue of human insulin
9. [Lys (B28, Pro (B29)]-human insulin: Effects of injection time on postprandial glycemia
10. Metabolic efficacy of preprandial administration of Lys (B28), Pro (B29) human insulin analog in IDDM patients
11. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function
12. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type-2 diabetic patients
13. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects
14. Influence of food intake on the absorption and effects of glipizide in diabetic and in healthy subjects
15. Effects on the hypoglycemic drugs Repaglinide and Glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells
16. N-(Cyclohexylcarbonyl)-D-phenylalanines and related compounds: A new class of oral hypoglycemic agents
17. β-cells in type II diabetes mellitus
18. Hypoglycemic and insulinotrophic effects of a novel oral antidiabetic agent, (-)-N-(trans-4-isopropyl-cyclohexanecarbonyl)-D-phenylalanine (A-4166)
19. Hypoglycemic effects of the novel antidiabetic agent repaglinide in rats and dogs
20. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycemic agents, NN623 and A4166
21. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells
22. + concentrations
23. + channel in insulin secreting cells
24. Pancreatic beta-cell KATP channel activity and membrane binding studies with nateglinide: A comparison with sulfonylureas and repaglinide
25. Stimulating activity of A-4166 on insulin release in situ hamster pancreatic perfusion
26. Stimulation of insulin and somatostatin release by two meglitinide analogs
27. Early insulin release effectively improves glucose tolerance: Studies in two rodent models of type 2 diabetes mellitus